Journal article
Type I interferon differential therapy for erythroleukemia: Specificity of STAT activation
Blood, Vol.101(7), pp.2727-2735
2003
Abstract
Type I interferons (IFNs), pleiotropic cytokines with antiviral, antiproliferative, apoptotic, and immunoregulatory functions, are efficacious in the treatment of malignancies, viral infections, and autoimmune diseases. Binding of these cytokines to their cognate receptor leads to activation of the Jak-signal transducers and activators of transcription (STAT) signaling pathway and altered gene expression. This signal pathway has been intensely studied using human IFN-α2 and IFN-β. However, there are over 14 human IFN-α subtypes and over 10 murine IFN-α subtypes, with a single IFN-β subtype in both species. J2E cells are immortalized at the proerythroblast stage of development and produce a rapid and fatal erythroleukemia in vivo. These cells retain the ability to respond to erythropoietin in vitro by proliferating, differentiating, and remaining viable in the absence of serum. Here, we show that J2E cells are also functionally regulated differentially by IFN subtype treatment in vitro. A novel finding was the selective activation of STAT and mitogen-activated protein kinase (MAPK) molecules by different subtypes binding the IFN receptor. These findings indicate distinct effects for individual type I IFN subtypes, which are able to differentially activate members of the STAT and MAPK family. Finally, we investigated the efficacy of IFN naked DNA therapy in treating J2E-induced erythroleukemia in athymic nude mice. IFN subtypes differentially regulated the onset of erythroleukemia with delayed onset and increased survival, possibly via a reduction in cell viability, and enhanced antiproliferative and apoptotic effects observed for IFNA6 and IFNA9treatment, respectively. Moreover, these data highlight the necessity to choose the best IFN subtype in disease treatment.
Details
- Title
- Type I interferon differential therapy for erythroleukemia: Specificity of STAT activation
- Authors/Creators
- V.S. Cull (Author/Creator) - Murdoch UniversityP.A. Tilbrook (Author/Creator) - Murdoch UniversityE.J. Bartlett (Author/Creator) - Murdoch UniversityN.L. Brekalo (Author/Creator) - Murdoch UniversityC.M. James (Author/Creator) - Murdoch University
- Publication Details
- Blood, Vol.101(7), pp.2727-2735
- Publisher
- American Society of Hematology
- Identifiers
- 991005542283607891
- Copyright
- 2011 American Society of Hematology
- Murdoch Affiliation
- School of Veterinary and Biomedical Sciences
- Language
- English
- Resource Type
- Journal article
UN Sustainable Development Goals (SDGs)
This output has contributed to the advancement of the following goals:
Source: InCites
Metrics
30 Record Views
InCites Highlights
These are selected metrics from InCites Benchmarking & Analytics tool, related to this output
- Collaboration types
- Domestic collaboration
- Citation topics
- 1 Clinical & Life Sciences
- 1.6 Immunology
- 1.6.1264 STAT3 Signaling
- Web Of Science research areas
- Hematology
- ESI research areas
- Clinical Medicine